VP-14637 ViroPharma.
VP-14637 is the lead compound in a series of low molecular weight viral replication inhibitors which are under preclinical investigation by ViroPharma for the potential treatment of RSV infection [322651]. Phase I trials designed to evaluate the safety and pharmacokinetic prpfile of VR-14637 in healthy human volunteers have begun [385870]. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity [363716], [361097].
McKimm-Breschkin
J
J
Biomolecular Research Institute, 343 Royal Parade, Parkville, VIC 3052, Australia. jenny.mckimm-breschkin@bioresi.com.au
D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational; D006801:Humans; D006835:Hydrazones; D010636:Phenols / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000821:virology; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects; D013329:Structure-Activity Relationship; D013777:Tetrazoles / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity
D000998:Antiviral Agents; D015507:Drugs, Investigational; D006835:Hydrazones; D010636:Phenols; D013777:Tetrazoles; C423511:VP-14637